quinazolines has been researched along with Uterine Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (38.46) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carson, DD; Engel, BJ | 1 |
| Bedard, PL; Castonguay, V; Chen, EX; Chen, H; Chen, Z; Clarke, B; Cohen, B; Hirte, HW; Hotte, SJ; Ivy, SP; Kamel-Reid, S; Liu, G; McGarrity, A; Oza, AM; Razak, AR; Reedijk, M; Sahebjam, S; Siu, LL; Wang, L; Zhang, T; Zhang, WJ | 1 |
| Muggia, F; Teplinsky, E | 1 |
| Azodi, M; Bellone, S; Bonazzoli, E; Bortolomai, I; Cocco, E; English, DP; Lopez, S; Nicoletti, R; Ratner, E; Roque, DM; Rutherford, TJ; Santin, AD; Schwab, CL; Schwartz, PE; Silasi, DA | 1 |
| Borger, DR; Byron, VF; DiGloria, CM; Foster, R; Groeneweg, JW; Growdon, WB; Hernandez, SF; Kim, M; Lopez, H; Rueda, BR; Scialabba, V; Tambouret, R; Zhang, L | 1 |
| Borger, D; Chisholm, S; Foster, R; Growdon, WB; Hernandez, SF; Rueda, BR | 1 |
| Bai, Y; Black, J; Carvajal-Hausdorf, DE; Rimm, DL; Santin, AD; Schalper, KA | 1 |
| Bolshakov, S; Dicker, A; Korchin, B; Lahat, G; Lazar, A; Lev, D; Merritt, W; Nguyen, T; Pollock, RE; Ren, W; Sood, A; Wei, C | 1 |
| Golabi, N; Jean-Claude, BJ; Larroque-Lombard, AL; Todorova, M; Williams, C | 1 |
| Al-Hendy, A; Copland, JA; Young, SL | 1 |
| Ben-Bassat, H; Hartzstark, Z; Klein, BY; Laufer, N; Levitzki, R; Rojansky, N; Shlomai, Z; Shushan, A | 1 |
| Ben-Bassat, H; Klein, BY; Laufer, N; Mishani, E; Rojansky, N; Shushan, A | 1 |
| Nowak, RA | 1 |
2 review(s) available for quinazolines and Uterine Neoplasms
| Article | Year |
|---|---|
Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
Topics: Adenocarcinoma, Mucinous; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Female; Genes, erbB-2; Humans; Lapatinib; Maytansine; Molecular Targeted Therapy; Ovarian Neoplasms; Quinazolines; Trastuzumab; Uterine Neoplasms | 2014 |
Potential nonhormonal therapeutics for medical treatment of leiomyomas.
Topics: Bexarotene; Female; Heparin; Humans; Interferon-alpha; Leiomyoma; ortho-Aminobenzoates; Piperidines; Pyridones; Quinazolines; Quinazolinones; Reproduction; Tetrahydronaphthalenes; Thiazolidinediones; Tocopherols; Uterine Neoplasms | 2004 |
1 trial(s) available for quinazolines and Uterine Neoplasms
| Article | Year |
|---|---|
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Colorectal Neoplasms; Female; Humans; Kidney Neoplasms; Leiomyosarcoma; Male; Middle Aged; Neoplasms; Quinazolines; Sarcoma, Endometrial Stromal; Thyroid Neoplasms; Treatment Outcome; Uterine Neoplasms; Young Adult | 2013 |
10 other study(ies) available for quinazolines and Uterine Neoplasms
| Article | Year |
|---|---|
Activated EGFR stimulates MUC1 expression in human uterine and pancreatic cancer cell lines.
Topics: Blotting, Western; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Female; Gene Expression; Humans; Mucin-1; Pancreatic Neoplasms; Quinazolines; Rosiglitazone; Thiazolidinediones; Tyrphostins; Uterine Neoplasms | 2013 |
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; In Vitro Techniques; Mice; Mice, SCID; Middle Aged; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Gene Amplification; Gene Expression; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Tumor Burden; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Cell Cycle; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Cystadenoma, Serous; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Phosphatidylinositol 3-Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
Topics: Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cohort Studies; Extracellular Space; Female; Fluorescent Antibody Technique; Humans; Intracellular Space; Lapatinib; Maytansine; Middle Aged; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Protein Domains; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Tissue Array Analysis; Trastuzumab; Uterine Neoplasms | 2017 |
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Muscle Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Tumor Cells, Cultured; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2008 |
Synthesis and uptake of fluorescence-labeled Combi-molecules by P-glycoprotein-proficient and -deficient uterine sarcoma cells MES-SA and MES-SA/DX5.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Comet Assay; Dansyl Compounds; DNA; DNA Damage; ErbB Receptors; Female; Flow Cytometry; Half-Life; Humans; Magnetic Resonance Spectroscopy; Microscopy, Fluorescence; Quinazolines; Sarcoma; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship; Uterine Neoplasms | 2010 |
The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth.
Topics: Adult; Apoptosis; Cell Cycle; Cell Division; Cells, Cultured; Enzyme Inhibitors; ErbB Receptors; Estradiol; Female; Humans; Leiomyoma; Myometrium; Phosphorylation; Progesterone; Protein-Tyrosine Kinases; Quinazolines; Tyrphostins; Uterine Neoplasms | 2004 |
Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Female; Genistein; Humans; Leiomyoma; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Uterine Neoplasms | 2007 |
Novel therapeutic strategies for leiomyomas: targeting growth factors and their receptors.
Topics: Antineoplastic Agents; Blotting, Western; Chromatography, Liquid; Female; Growth Inhibitors; Growth Substances; Humans; Hysterectomy; Hysteroscopy; Immunohistochemistry; Interferon-alpha; Leiomyoma; Phenoxyacetates; Piperidines; Polymers; Protein Synthesis Inhibitors; Pyridones; Quinazolines; Quinazolinones; Receptors, Growth Factor; Uterine Neoplasms | 2000 |